AIM AIM ImmunoTech

$AIM The collaborators for the new trial are interesting: Dr. Kalinski; Dr Edwards, of UPMC Magee Womens Hospital; Northwest Biotherapeutics $NWBO AIM ImmunoTech Inc. There had been rumors about a collaboration, so it is interesting to see what might come of it.

$AIM High up in the steep mountains of clinical trials lived a tiny engine named Ampligen. He wasn’t one of the shiny, billion-dollar locomotives from Big Pharma. No private jets, no army of marketing cars, no endless coal from deep-pocketed investors. Ampligen was small, a bit battered from years of rough tracks, and ran on something the bigger engines mostly ignored: pure, stubborn belief that he could help people the others had written off. One day a long train of patients rolled into the station. The cars were heavy—metastatic pancreatic cancer, the kind of mountain that kills more than 100,000 people a year in the U.S. and Europe alone. Other engines had tried the climb. Some had given up. Some had chugged a little ways then stalled. The big engines looked at the load and said, “Too steep. Too toxic. Not worth our coal.” Ampligen rolled up, smaller than the rest. “I think I can,” e said.The bigger engines laughed.“You’re just a little dsRNA engine. You don’t even have a full FDA

$AIM Ten years and three reverse splits. Tommy, you have kept the shorts very happy while patients and stockholders have suffered in my opinion. Do you really think you are a hero to patients and stockholders?

$AIM Reviewing the 9/30/2026 annual report and laughed. The average age of the leadership team is >75. No AIM is not a retirement community. Name/Age/Position Thomas K. Equels, M.S., J.D. / 73 /Chief Executive Officer, President and Director Nancy Bryan, MBA / 68 / Director William M. Mitchell, M.D., Ph.D. / 91 / Chair of the Board and Director Ted D. Kellner / 79 / Director David Chemerow, MBA / 74 /Director Peter W. Rodino III, Esq. / 74 / Chief Operating Officer, General Counsel and Secretary Robert Dickey IV, MBA / 70 / Chief Financial Officer

$AIM Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Dr Kalinski and Dr Edwards are starting a new trial. This was mentioned back in June. h/T

$AIM Just food for thought. About a month ago I Grok'd what was a microcap company that might 10x. Besides a bunch of warning caveats it gave one example stock. This one.

$AIM this company spends more time figuring out new ways to scam new investors then it does getting their drug over the finish line with a deal with big Pharma. Pathetic leadership

$AIM Intellectual Property & Patent Expansions Long COVID Protection: AIM significantly expanded its global patent portfolio, securing patent protection in Europe and the United Kingdom covering Ampligen for Long COVID, extending exclusivity through June 2041. Oncology Combinations: The U.S. Patent and Trademark Office (USPTO) granted a broad patent covering the use of Ampligen in combination with pembrolizumab (Keytruda) for cancer treatment, protecting the IP landscape through 2039.

$AIM "AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential" Although they often issued pumping press releases along these lines, Ampligen has never been used to treat any human for any infection. The pumps are all based on animal studies. Alferon has been used for infections, (chiefly for genital warts), but Alferon is a form of interferon-alpha that is difficult and expensive to produce and is more or less obsolete (the last time Alferon was sold was in March 2008).

$AIM There was an uptick in short interest in Aug-Sep, but it appears to be coming back down. Most likely, the short selling was probably done by some of the toxic financiers that the company has resorted to using. Shares Outstanding 39.89M Float 27.58M % Held by Insiders 0.67% % Held by Institutions 2.88% Shares Short (10/15/2026) 1.08M Short Ratio (10/15/2026) 0.81 Short % of Float (10/15/2026) 2.72% Short % of Shares Outstanding (10/15/2026) 2.71% Shares Short (prior month 9/15/2026) 2.77M

$AIM you wonder why it spikes up a little.? I scooped up a little bit of shares the croocks trade in between own accounts to get us lower…

$AIM once upon a time I had 1% of the company. If they had taken the bad deal from Roswell I would have been robbed but I would have been rather happy. If the next split comes along I’ll be left with 2000 shares . Not much good can come from that. The hedgies said they would clean us out and after 30+ years they have nearly succeeded

$AIM this ticker could absolutely skyrocket with volume. Happy to be sitting on some shares

From $AIM 's recent SEC filing: "Our common stock is listed on the Exchange. In order to maintain this listing, we must maintain a certain share price, financial and share distribution targets, including maintaining a minimum amount of stockholders’ equity and a minimum number of public stockholders. In addition to these objective standards, the Exchange may delist the securities of any issuer ...if an issuer’s securities sell at what the Exchange considers a “low selling price” which the exchange generally considers $0.10 per share, the Exchange may suspend trading of the common stock, until the issuer corrects this via a reverse split of shares after notification by the Exchange" They already have shareholder's approve to do another 1-for-25 reverse split. Given the trend on the share price, it is possible that this could happen before the end of this year.